Treatment of AF in American Indians and Alaska Natives: Insights From the NCDR PINNACLE-AF Registry

TY - JOUR

T1 - Treatment of AF in American Indians and Alaska Natives

T2 - Insights From the NCDR PINNACLE-AF Registry

AU - Khalid, Umair

AU - Marzec, Lucas N.

AU - Mantini, Nicholas

AU - Manson, Spero M.

AU - Doros, Gheorghe

AU - Cannon, Christopher P.

AU - Song, Yang

AU - Dong, Liyan

AU - Hsu, Jonathan C.

AU - Jeong, Mark Y.

AU - Virani, Salim S.

AU - Maddox, Thomas M.

N1 - Funding Information: Please note: This research was supported by the American College of Cardiology's National Cardiovascular Data Registry (NCDR). The views expressed in this paper represent those of the authors and do not necessarily represent the official views of the NCDR or its associated professional societies, identified at http://cvquality.acc.org/ncdr. Dr. Cannon has received research grants (all >$10,000) from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Merck, and Pfizer; and has received consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, and Sanofi (>$10,000). Dr. Hsu has received honoraria from Medtronic, Boston Scientific, Abbott, Biotronik, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Biosense Webster; has received research grants from Biosense Webster and Biotronik; and has equity in Acutus Medical and Vektor Medical. Dr. Virani has received research grants from the U.S. Department of Veterans Affairs, the World Heart Federation, and the Tahir and Jooma Family; has received an honorarium from the American College of Cardiology (associate editor, Innovations, ACC.org); and is a member of the steering committee for the PALM (Patient and Provider Assessment of Lipid Management) registry (no financial remuneration). Dr. Maddox has received grant funding from the National Center for Advancing Translational Sciences (grant 1U24TR002306-01: A National Center for Digital Health Informatics Innovation); is a consultant for Creative Educational Concepts and Atheneum Partners; and has received honoraria from the University of Utah (May 2017), New York-Presbyterian (September 2017), Westchester Medical Center (October 2017), Sentara Heart Hospital (December 2018), and the Henry Ford Health System (March 2019); is currently employed as a cardiologist and the executive director of the Healthcare Innovation Lab at BJC HealthCare/Washington University School of Medicine, in which capacity he is advising Myia Labs, for which his employer is receiving equity compensation in the company but he is receiving no individual compensation from the company; and is a compensated director for a New Mexico–based foundation, the J.F. Maddox Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: This research was supported by the American College of Cardiology’s National Cardiovascular Data Registry (NCDR). The views expressed in this paper represent those of the authors and do not necessarily represent the official views of the NCDR or its associated professional societies, identified at http://cvquality.acc.org/ncdr . Dr. Cannon has received research grants (all >$10,000) from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Merck, and Pfizer; and has received consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, and Sanofi (>$10,000). Dr. Hsu has received honoraria from Medtronic, Boston Scientific, Abbott, Biotronik, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Biosense Webster; has received research grants from Biosense Webster and Biotronik; and has equity in Acutus Medical and Vektor Medical. Dr. Virani has received research grants from the U.S. Department of Veterans Affairs, the World Heart Federation, and the Tahir and Jooma Family; has received an honorarium from the American College of Cardiology (associate editor, Innovations, ACC.org ); and is a member of the steering committee for the PALM (Patient and Provider Assessment of Lipid Management) registry (no financial remuneration). Dr. Maddox has received grant funding from the National Center for Advancing Translational Sciences (grant 1U24TR002306-01: A National Center for Digital Health Informatics Innovation); is a consultant for Creative Educational Concepts and Atheneum Partners; and has received honoraria from the University of Utah (May 2017), New York-Presbyterian (September 2017), Westchester Medical Center (October 2017), Sentara Heart Hospital (December 2018), and the Henry Ford Health System (March 2019); is currently employed as a cardiologist and the executive director of the Healthcare Innovation Lab at BJC HealthCare/Washington University School of Medicine, in which capacity he is advising Myia Labs, for which his employer is receiving equity compensation in the company but he is receiving no individual compensation from the company; and is a compensated director for a New Mexico–based foundation, the J.F. Maddox Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2020/6/2

Y1 - 2020/6/2

UR - https://www.scopus.com/pages/publications/85084754253

U2 - 10.1016/j.jacc.2020.03.069

DO - 10.1016/j.jacc.2020.03.069

M3 - Letter

C2 - 32466892

AN - SCOPUS:85084754253

SN - 0735-1097

VL - 75

SP - 2749

EP - 2750

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 21

ER -